Abstract
With the ultimate goal of discovering new anticancer agents, the National Cancer Institute (NCI), through its Developmental Therapeutics Program, uses a semiautomatic procedure (Monks et al., 1991) to annually evaluate thousands of compounds for their ability to inhibit the growth of each of a panel of 60 human tumor cell lines (reviewed in Boyd and Pauli, 1995). The panel includes nine subpanels, each representing a specific tumor type, viz., leukemia, melanoma, and cancers of the brain, breast, colon, kidney, lung (non-small cell), ovary, and prostate, and each consisting of at least six tumor cell lines, except for the prostate cancer subpanel which consists of only two cell lines. The results of these tests, viz., GI50, TGI and LC50 values (the concentrations of an agent required to effect 50% growth inhibition, total growth inhibition and 50% cell-kill, respectively) have been, and are being, stored in an electronic database.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boyd, M.R. and Pauli, K.D.: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel. Res., 34 (1995) 91–109.
Chang, T.K.H., Weber, G.F., Crespi, C.L. and Waxman, D.J.: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53 (1993) 5629–5637.
Dockham, P.A., Lee, M.-O. and Sladek, N.E.: Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol., 43 (1992) 2453–2469.
Fitzsimmons, S. A., Workman, P., Grever, M., Pauli, K., Camalier, R. and Lewis, A. D.: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst., 88 (1996) 259–269.
Hornbeck, P., Winston, S.E. and Fuller, S.A.: Enzyme-linked immunosorbent assays (ELISA). In Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (Eds.), Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, N. Y., 1991, pp 11.2.1–11.2.22.
Lee, J.-S., Pauli, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Tito Fojo, A. and Bates, S.E.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46 (1994) 627–638.
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Pauli, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J. and Boyd, M.: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83 (1991) 757–766.
Pauli, K.D., Shoemaker, R.H., Hodes, L., Monks, A., Scudiero, D.A., Rubinstein, L., Plowman, J. and Boyd, M.R.: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81 (1989) 1088–1092.
Sladek, N.E.: Oxazaphosphorine-specific acquired cellular resistance. In Teicher, B.A. (Ed.), Drug Resistance in Oncology, Marcel Dekker, N.Y., 1993, pp. 375–411.
Sladek, N.E.: Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In Powis, G. (Ed.), Anticancer Drugs: Reactive Metabolism and Drug Interactions, Pergamon Press, United Kingdom, 1994, pp. 79–156.
Sladek, N.E. and Lee, M.-O.: The use of immortalized mouse L1210/OAP cells established in culture to study the major class 1 aldehyde dehydrogenase-catalyzed oxidation of aldehydes in intact cells. Adv. Exp. Med. Biol., 328 (1993) 51–62.
Sladek, N.E. and Sreerama, L.: Cytosolic class-3 and class-1 aldehyde dehydrogenase activities (ALDH-3 and ALDH-1, respectively) in human primary breast tumors. Proc. Am. Assoc. Cancer Res., 36 (1995) 325.
Sreerama, L. and Sladek, N.E.: Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol., 45 (1993) 2487–2505.
Sreerama, L. and Sladek, N.E.: Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res., 54 (1994) 2176–2185.
Sreerama, L. and Sladek, N.E.: Overexpression of glutathione S-transferases, DT-diaphorase and an apparently tumor-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumors and mucoepidermoid carcinomas of the parotid gland. Arch. Oral Biol., 41 (1996) In press.
Uckun, F.M., Chandan-Langlie, M., Dockham, P.A., Aeppli, D. and Sladek N.E.: Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. Leukemia and Lymphoma, 13 (1994) 417–428.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sreerama, L., Sladek, N.E. (1996). Class 1 and Class 3 Aldehyde Dehydrogenase Levels in the Human Tumor Cell Lines Currently Used by the National Cancer Institute to Screen for Potentially Useful Antitumor Agents. In: Weiner, H., Lindahl, R., Crabb, D.W., Flynn, T.G. (eds) Enzymology and Molecular Biology of Carbonyl Metabolism 6. Advances in Experimental Medicine and Biology, vol 414. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5871-2_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5871-2_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7692-7
Online ISBN: 978-1-4615-5871-2
eBook Packages: Springer Book Archive